Dietary Bioactive Ingredients Modulating the cAMP Signaling in Diabetes Treatment

Yanan Wang1, Qing Liu2, Seong-Gook Kang3

  • 1Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, China.

Nutrients
|September 28, 2021
PubMed

Insights

Dietary bioactive compounds can improve diabetes by targeting cyclic adenosine monophosphate (cAMP) signaling. These compounds modulate cAMP in various organs, offering potential for diabetes prevention and treatment.

Area of Science:

  • Endocrinology and Metabolism
  • Nutritional Science
  • Molecular Biology

Background:

  • Diabetes prevalence is rising globally, necessitating novel therapeutic strategies.
  • Cyclic adenosine monophosphate (cAMP) is a crucial intracellular second messenger regulating metabolism and glucose homeostasis across multiple organs.
  • Dietary compounds show promise in managing diabetes, potentially through interactions with the cAMP signaling pathway.

Purpose of the Study:

  • To review the role of cAMP in glucose homeostasis across various organs.
  • To explore how dietary bioactive ingredients interact with cAMP signaling.
  • To highlight the therapeutic potential of these ingredients in diabetes.

Main Methods:

  • Literature review of studies on cAMP signaling in glucose metabolism.
  • Analysis of research on dietary compounds affecting cAMP pathways.
  • Synthesis of information on the impact of these interactions on diabetes pathogenesis.

Main Results:

  • cAMP plays diverse roles in glucose regulation in organs like the pancreas, liver, gut, muscle, adipose tissue, brain, and kidney.
  • Numerous bioactive food ingredients modulate cAMP signaling pathways.
  • Activation or inhibition of cAMP by these ingredients can improve diabetic conditions.

Conclusions:

  • Dietary bioactive ingredients targeting cAMP signaling hold significant potential for diabetes management.
  • Understanding these interactions can lead to new preventative and therapeutic approaches for diabetes.
  • Further research into these compounds could offer novel strategies for improving glucose homeostasis.

Related Concept Videos

Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
4.9K
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.7K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
7.0K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
320
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
2.1K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
293